0000000000267903

AUTHOR

Jeanne-marie Jacquet

showing 3 related works from this author

Booster vaccination after neonatal priming with acellular pertussis vaccine.

2010

After a birth dose of acellular pertussis (aP) and diphtheria (DT)aP-hepatitis B virus (HBV)-inactivated polio vaccine (IPV)/ Haemophilus influenza type b (Hib) at 2, 4, and 6 months, a booster dose of DTaP-HBV-IPV/Hib at 12 to 23 months induced strong anti-pertussis booster responses. Thus, neonatal aP priming did not lead to immune tolerance to pertussis antigens. However, it elicited bystander interference on HBV, Hib, and diphtheria responses.

Whooping CoughFilamentous haemagglutinin adhesinImmunization SecondaryBooster dosemedicine.disease_causecomplex mixturesVirusPolio vaccineVaccines AcellularmedicineHumansWhooping coughHepatitis B virusPertussis VaccineDose-Response Relationship Drugbusiness.industryDiphtheriaVaccinationInfant Newbornvirus diseasesInfantmedicine.diseasePrognosisVirologyVaccinationPediatrics Perinatology and Child HealthImmunologybusinessFollow-Up StudiesThe Journal of pediatrics
researchProduct

Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine).

2009

Combination vaccines that include multiple antigens within one formulation are now widely accepted as an effective means of eliciting protection against several diseases at the same time. Owing to improvements in quality and convenient modes of administration, they have become part of routine pediatric practice. Hexavalent vaccines, including diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b antigens represent the latest advance in the development of combination vaccines. Over 8 years since its first licensure, this review looks at the immunogenicity, efficacy and safety profile of the only hexavalent pediatric vaccine currently in use--Infanrix hexa (diph…

ImmunologyPostmarketing surveillancemedicine.disease_causeDiphtheria-Tetanus-acellular Pertussis Vaccinescomplex mixturesPneumococcal conjugate vaccineDrug DiscoverymedicineProduct Surveillance PostmarketingHumansVaccines CombinedDiphtheria-Tetanus-acellular Pertussis VaccinesHaemophilus VaccinesPharmacologyClinical Trials as TopicTetanusbusiness.industryDiphtheriaPoliovirusmedicine.diseaseVirologyPoliomyelitisVaccinationPoliovirus Vaccine InactivatedImmunologyMolecular Medicinebusinessmedicine.drugExpert review of vaccines
researchProduct

Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants

2007

Objectives Because young infants are at highest risk of pertussis complications, this study assessed whether neonatal acellular pertussis (aP) vaccination could provide earlier immunity. Study design Neonates (n = 121) were randomly assigned (1:1) to receive either aP or hepatitis B vaccine (HBV) (controls) vaccine at birth, followed by vaccination with DTaP-HBV-IPV/Hib at 2, 4 and 6 months. Immune responses were measured. Reactogenicity was assessed for 7 days after each dose. Results The aP birth dose was followed by few adverse events. Reactogenicity of subsequent vaccine doses did not differ between groups. Seven serious adverse events were reported from each group; none were related to…

MaleHBsAgHepatitis B vaccineTime Factorsddc:616.07Bordetella pertussisDrug Administration ScheduleVaccines AcellularDouble-Blind MethodmedicineHumansWhooping coughPertussis VaccineVaccines Acellular/administration & dosageReactogenicityTetanusbusiness.industryDiphtheriaAge FactorsInfant NewbornInfantAntibodies Bacterial/bloodmedicine.diseasePertussis Vaccine/administration & dosageAntibodies BacterialVaccinationImmunoglobulin G/bloodImmunoglobulin GPediatrics Perinatology and Child HealthImmunologyFeasibility StudiesFemalePertactinbusinessBordetella pertussis/immunologyFollow-Up Studies
researchProduct